# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Joel Beatty maintains Immutep (NASDAQ:IMMP) with a Outperform and lowers the price target from $7 to $6.
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD's anti-PD-1 therapy, and standard chemothera...
Capital One analyst Naureen Quibria initiates coverage on Immutep (NASDAQ:IMMP) with a Overweight rating and announces Price...
– Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial e...